Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inozyme Pharma, Inc. - Common Stock (NQ:INZY)

3.950 +2.530 (+178.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inozyme Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency 
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented 
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma: Q4 Earnings Insights
Via Benzinga
6 Analysts Have This to Say About Inozyme Pharma
Via Benzinga
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024
INZY stock results show that Inozyme Pharma missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free 
Via Benzinga
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That May Plunge In March
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion - 
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in Upcoming Investor Conferences
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Posts Encouraging Data From Rare Calcification Disorders
Inozyme Pharma Inc (NASDAQ: INZY) announced interim safety, pharmacokinetic (PK), pharmacodynamic (PD), and exploratory efficacy data from its ongoing Phase 1/2 trials of INZ-701 in adults with 
Via Benzinga
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
From Inozyme Pharma Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback